Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.

@article{Syed2013ExtendedreleaseIN,
  title={Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.},
  author={Yahiya Y. Syed and Gillian M. Keating},
  journal={CNS drugs},
  year={2013},
  volume={27 10},
  pages={851-61}
}
Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prevention of relapse to opioid dependence, after opioid detoxification. The clinical efficacy of this formulation in patients with opioid dependence was demonstrated in a 24-week… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine

Progress in Neuro-Psychopharmacology and Biological Psychiatry • 2016
View 1 Excerpt
Highly Influenced

Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science • 2016

Similar Papers

Loading similar papers…